Advertisement

Journal of Radioanalytical and Nuclear Chemistry

, Volume 322, Issue 2, pp 1133–1138 | Cite as

Appraisement of 186/188Re-HEDP, a new compositional radiopharmaceutical

  • Zahra Pourhabib
  • Hassan RanjbarEmail author
  • Ali Bahrami Samani
  • Ali Asghar Shokri
Article
  • 16 Downloads

Abstract

Undoubtedly radionuclide therapy is the next phase of nuclear medicine development. 188Re-HEDP and 186Re-HEDP are therapeutic radiopharmaceuticals which have been used to treat bone metastases. With regard to their complementary features, in this study, as new idea their combined effects have been investigated with preparing the cocktail of 188/186Re-HEDP with radiochemical purity nearly 99%. The 188/186Re-HEDP biodistribution was checked in rats’ tissues up to 72 h. The produced 188/186Re-HEDP properties suggest a new bone palliative radiopharmaceutical to overcome bone metastases.

Keywords

186/188Re-HEDP Combined radionuclide therapy Pain palliation Biodistribution 

Notes

Compliance with ethical standards

Ethical approval

All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.

References

  1. 1.
    Chaturvedi S, Mishra AK (2016) Small molecule radiopharmaceuticals—a review of current approaches. Front Med 3:5CrossRefGoogle Scholar
  2. 2.
    Debnath S, Babu MN, Kumar GV (2015) Radiopharmaceuticals and their therapeutic applications in health care system. Asian J Res Pharm Sci 5(4):221–226CrossRefGoogle Scholar
  3. 3.
    Knapp FR, Dash A (eds) (2016) Introduction: radiopharmaceuticals play an important role in both diagnostic and therapeutic nuclear medicine. In: Radiopharmaceuticals for therapy. Springer, Berlin, pp 3–23Google Scholar
  4. 4.
    Volkert W et al (1991) Therapeutic radionuclides: production and decay property considerations. J Nucl Med 32(1):174–185PubMedGoogle Scholar
  5. 5.
    Yeong C-H, Cheng M-H, Ng K-H (2014) Therapeutic radionuclides in nuclear medicine: current and future prospects. J Zhejiang Univ Sci B 15(10):845–863PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Eary JF, Brenner W (2007) Nuclear medicine therapy. CRC Press, Boca RatonCrossRefGoogle Scholar
  7. 7.
    Fischer M, Kampen WU (2012) Radionuclide therapy of bone metastases. Breast Care 7(2):100–107PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Kassis AI (2008) Therapeutic radionuclides: biophysical and radiobiologic principles. Semin Nucl Med 38(5):358–366PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Kothari K et al (1998) Preparation of 186Re complexes of dimercaptosuccinic acid and hydroxy ethylidine diphosphonate. Mod Trends Radiopharm Diagn Ther 29:539–555Google Scholar
  10. 10.
    Bai H et al (1996) Preparation of a cold kit of 186Re(Sn)-HEDP. J Radioanal Nucl Chem 206(1):43–50CrossRefGoogle Scholar
  11. 11.
    Kothari K et al (1999) Preparation, stability studies and pharmacological behavior of [186Re] Re-HEDP. Appl Radiat Isot 51(1):51–58PubMedCrossRefGoogle Scholar
  12. 12.
    Ramakurup REK et al (2018) Rhenium-188 hydroxyethane 1,1-diphosphonic acid (HEDP) for bone pain palliation using BARC-HEDP kits versus Pars-HEDP kits: a comparison on preparation and performance aspects at hospital radiopharmacy. Indian J Nucl Med 33(4):302PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Sharma R et al (2017) In vitro evaluation of 188Re-HEDP: a mechanistic view of bone pain palliations. Cancer Biother Radiopharm 32(5):184–191PubMedCrossRefGoogle Scholar
  14. 14.
    Biersack H-J et al (2011) Palliation and survival after repeated 188Re-HEDP therapy of hormone-refractory bone metastases of prostate cancer: a retrospective analysis. J Nucl Med 52(11):1721–1726PubMedCrossRefGoogle Scholar
  15. 15.
    Giannakenas C et al (2000) Preliminary results of the use of Re-186-HEDP for palliation of pain in patients with metastatic bone disease. Am J Clin Oncol 23(1):83–88PubMedCrossRefGoogle Scholar
  16. 16.
    Lambert B, de Klerk JM (2006) Clinical applications of 188Re-labelled radiopharmaceuticals for radionuclide therapy. Nucl Med Commun 27(3):223–229PubMedCrossRefGoogle Scholar
  17. 17.
    Lange R et al (2016) Treatment of painful bone metastases in prostate and breast cancer patients with the therapeutic radiopharmaceutical rhenium-188-HEDP. Clinical benefit in a real-world study. Nuklearmedizin 55(5):188–195PubMedCrossRefGoogle Scholar
  18. 18.
    Liepe K et al (2003) Therapeutic efficiency of rhenium-188-HEDP in human prostate cancer skeletal metastases. Br J Cancer 89(4):625PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Limouris G et al (1997) Rhenium-186-HEDP palliative treatment in disseminated bone metastases due to prostate cancer. Anticancer Res 17(3B):1699–1704PubMedGoogle Scholar
  20. 20.
    Lyra M et al (2003) Radionuclide Therapy for Oncology – Current Status and Future Aspects, Rhenium-186-HEDP dosimetry and multiple bone metastases palliation therapy effects, Mediterra publishersGoogle Scholar
  21. 21.
    Minutoli F et al (2006) 186Re-HEDP in the palliation of painful bone metastases from cancers other than prostate and breast. Q J Nucl Med Mol Imaging 50(4):355PubMedGoogle Scholar
  22. 22.
    Orsini F et al (2012) Palliation and survival after repeated 188Re-HEDP therapy of hormone-refractory bone metastases of prostate cancer: a retrospective analysis. J Nucl Med 53(8):1330PubMedCrossRefGoogle Scholar
  23. 23.
    Pirayesh E et al (2013) Phase 2 study of a high dose of 186Re-HEDP for bone pain palliation in patients with widespread skeletal metastases. J Nucl Med Technol 41(3):192–196PubMedCrossRefGoogle Scholar
  24. 24.
    Mallia MB et al (2016) A freeze-dried kit for the preparation of 188Re-HEDP for bone pain palliation: preparation and preliminary clinical evaluation. Cancer Biother Radiopharm 31(4):139–144PubMedCrossRefGoogle Scholar
  25. 25.
    Shinto AS et al (2018) Clinical utility of 188Rhenium-hydroxyethylidene-1,1-diphosphonate as a bone pain palliative in multiple malignancies. World J Nucl Med 17(4):228PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Ranjbar H et al (2015) Evaluation of 153Sm/177Lu-EDTMP mixture in wild-type rodents as a novel combined palliative treatment of bone pain agent. J Radioanal Nucl Chem 303(1):71–79CrossRefGoogle Scholar
  27. 27.
    Pourhabib Z et al (2019) Experimental and theoretical study of rhenium radioisotopes production for manufacturing of new compositional radiopharmaceuticals. Appl Radiat Isot 145:176–179PubMedCrossRefGoogle Scholar
  28. 28.
    Lin W-Y et al (1997) Rhenium-188 hydroxyethylidene diphosphonate: a new generator-produced radiotherapeutic drug of potential value for the treatment of bone metastases. Eur J Nucl Med 24(6):590–595PubMedGoogle Scholar
  29. 29.
    Zhi Y et al (2014) Preparation of 188Re-HEDP lyophilized kit for instant bone metastases therapy. Nucl Sci Tech 25(6):1–6Google Scholar
  30. 30.
    Verdera E et al (1997) Rhenium-188-HEDP-kit formulation and quality control. Radiochim Acta 79(2):113–118CrossRefGoogle Scholar
  31. 31.
    Liepe K et al (2003) Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases. J Nucl Med 44(6):953–960PubMedGoogle Scholar
  32. 32.
    Liepe K et al (2009) Autoradiographic studies of rhenium-188-hydroxyethylidine diphosphonate in normal skeleton and osteoblastic bone metastases in a rat model of metastatic prostate cancer. Nucl Med Commun 30(9):693–699PubMedCrossRefGoogle Scholar
  33. 33.
    Bergmann R et al (2016) 177Lu-labelled macrocyclic bisphosphonates for targeting bone metastasis in cancer treatment. EJNMMI Res 6(1):5PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Erfani M et al (2018) Radiolabeling of zoledronic acid with 188Re as a new palliative agent radiotracer in treatment of bone tumors. J Radioanal Nucl Chem 316(2):491–500CrossRefGoogle Scholar
  35. 35.
    Yousefnia H et al (2016) Preparation and biological assessment of 177Lu-BPAMD as a high potential agent for bone pain palliation therapy: comparison with 177Lu-EDTMP. J Radioanal Nucl Chem 307(2):1243–1251CrossRefGoogle Scholar

Copyright information

© Akadémiai Kiadó, Budapest, Hungary 2019

Authors and Affiliations

  • Zahra Pourhabib
    • 1
  • Hassan Ranjbar
    • 2
    Email author
  • Ali Bahrami Samani
    • 2
  • Ali Asghar Shokri
    • 1
  1. 1.Department of PhysicsPayame Noor University (PNU)TehranIran
  2. 2.Material and Nuclear Fuel Research SchoolNuclear Science and Technology Research InstituteTehranIran

Personalised recommendations